MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure
On July 19, 2017, Medovex Corp. (the “Company”) issued a press release relating to the first human cases being performed using its DenerveX Device, a copy of which is attached hereto as Exhibit 99.1.
The information contained in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information contained in this Current Report on Form 8-K constitutes material investor information that is not otherwise publicly available.
The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.
Item 9.01Financial Statements and Exhibits
(d)Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
MedoveX Corp. press release dated July 19, 2017 |
Medovex Corp. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 Exhibit 99.1 Medovex Corporation Announces First Human Cases Using Its DenerveX Device and First Revenue Events Highly Disruptive and Patented Less Invasive Device with Faster Recovery Time than Current Surgical Treatment Options for Facet Joint Syndrome ATLANTA,…To view the full exhibit click here